Ruxolitinib Cream in Children: What the 52-Week TRuE-AD3 Extension Shows

November 9, 2026

AI-generated illustration: Dr. Arsy Hydration Cream on Glass

Dr. Arsy Editorial Team · November 9, 2026

A 52-week report from TRuE-AD3 describes longer-term as-needed ruxolitinib cream use in children ages 2 to 11 with mild-to-moderate atopic dermatitis. The results add exposure data, but the extension lacked a vehicle control, which limits causal conclusions about long-term disease control.^[4]

From randomized treatment to an extension

Children originally assigned to 0.75% or 1.5% ruxolitinib cream continued their dose for 44 additional weeks, applying it twice daily only as needed. Children initially assigned to vehicle were re-randomized to one of the active strengths. A total of 282 children used ruxolitinib during the long-term period.

Reported safety and control

Application-site reactions occurred in 1.1%, and no serious treatment-related adverse events were reported. Among those initially randomized to active treatment, IGA 0/1 at week 52 was reported in 79.5% and 72.3% for the two strengths, with mean affected body surface area of 2.0% and 1.9%. Without a vehicle group after week eight, these figures describe participants remaining in the extension rather than a controlled one-year efficacy comparison.^[4]

Why labels and age limits still govern care

Trial findings do not replace a country’s current prescribing information, boxed warnings, body-surface-area limits, duration instructions or clinician assessment. Results in children ages 2–11 do not apply to infants. Separate trials and guidelines should be reviewed for approved use and monitoring.^{[14][16][18][19]}

Questions for the prescriber

Is the medicine approved for this child’s age and disease extent?
Which areas should be treated and for how long?
What does “as needed” mean in the written plan?
Which infections, medications or medical history change the decision?
When should response and adverse effects be reassessed?

Caregivers should use prescription eczema medicine only as directed and seek prompt help for fever, rapidly worsening pain, spreading redness, pus or clustered blisters.

Moisturizer context

Dr. Arsy Moisturizer #003 supports cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in the study above and does not reproduce the effects of prescription treatment, phototherapy or a care-delivery program.

Related research

Research and clinical references

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes